Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma. Robert Motzer, MD: There are now three different trials ...
Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of ...
1. Flush IO line with 20cc IO saline. If IO line does not flush easily, do not use. 2. If Patient is unconscious, no analgesia is required. If patient is conscious and responsive to pain, IO 2% ...
In this case-based segment on advanced renal cell carcinoma, Dr. Ornstein presents a patient who progresses after frontline immunotherapy plus VEGF receptor targeted therapy, with prior tolerability ...
Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2025 ASCO ...
Efficacy and safety of transarterial chemoembolization (TACE) plus sorafenib vs TACE alone in the treatment of non-resectable hepatocellular carcinoma: A systematic review and meta-analysis. (Bucher; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results